Literature DB >> 19540297

Glial cell activation in response to electroconvulsive seizures.

Linda Jansson1, Malin Wennström, Aki Johanson, Anders Tingström.   

Abstract

Electroconvulsive therapy (ECT) is a very efficient treatment for severe depression. However, cognitive side effects have raised concern to whether ECT can cause cellular damage in vulnerable brain regions. A few recent animal studies have reported limited hippocampal cell loss, while a number of other studies have failed to find any signs of cellular damage and some even report that electroconvulsive seizures (ECS; the animal counterpart of ECT) has neuroprotective effects. We previously have described gliogenesis in response to ECS. Loss of glial cells is seen in depression and de novo formation of glial cells may thus have an important therapeutic role. Glial cell proliferation and activation is however also seen in response to neuronal damage. The aim of the present study was to further characterize glial cell activation in response to ECS. Two groups of rats were treated with 10 ECS using different sets of stimulus parameters. ECS-induced changes in the morphology and expression of markers typical for reactive microglia, astrocytes and NG2+ glial cells were analyzed immunohistochemically in prefrontal cortex, hippocampus, amygdala, hypothalamus, piriform cortex and entorhinal cortex. We observed changes in glial cell morphology and an enhanced expression of activation markers 2 h following ECS treatment, regardless of the stimulus parameters used. Four weeks later, few activated glial cells persisted. In conclusion, ECS treatment induced transient glial cell activation in several brain areas. Whether similar processes play a role in the therapeutic effect of clinically administered ECT or contribute to its side effects will require further investigations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19540297     DOI: 10.1016/j.pnpbp.2009.06.007

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  33 in total

Review 1.  Roles of NG2 glial cells in diseases of the central nervous system.

Authors:  Jian-Ping Xu; Jie Zhao; Shao Li
Journal:  Neurosci Bull       Date:  2011-12       Impact factor: 5.203

Review 2.  Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?

Authors:  Mark J Niciu; Ioline D Henter; Gerard Sanacora; Carlos A Zarate
Journal:  World J Biol Psychiatry       Date:  2013-09-12       Impact factor: 4.132

Review 3.  Microglia Priming with Aging and Stress.

Authors:  Anzela Niraula; John F Sheridan; Jonathan P Godbout
Journal:  Neuropsychopharmacology       Date:  2016-09-08       Impact factor: 7.853

4.  The PPARγ agonist rosiglitazone prevents cognitive impairment by inhibiting astrocyte activation and oxidative stress following pilocarpine-induced status epilepticus.

Authors:  Sun Hong; Yu Xin; Wu HaiQin; Zhang GuiLian; Zhang Ru; Zhan ShuQin; Wang HuQing; Yao Li; Du Yun
Journal:  Neurol Sci       Date:  2011-09-14       Impact factor: 3.307

5.  Microglia and their LAG3 checkpoint underlie the antidepressant and neurogenesis-enhancing effects of electroconvulsive stimulation.

Authors:  Neta Rimmerman; Hodaya Verdiger; Hagar Goldenberg; Lior Naggan; Elad Robinson; Ewa Kozela; Sivan Gelb; Ronen Reshef; Karen M Ryan; Lily Ayoun; Ron Refaeli; Einat Ashkenazi; Nofar Schottlender; Laura Ben Hemo-Cohen; Claudia Pienica; Maayan Aharonian; Eyal Dinur; Koby Lazar; Declan M McLoughlin; Ayal Ben Zvi; Raz Yirmiya
Journal:  Mol Psychiatry       Date:  2021-10-14       Impact factor: 15.992

6.  Early responses to deep brain stimulation in depression are modulated by anti-inflammatory drugs.

Authors:  L Perez-Caballero; R Pérez-Egea; C Romero-Grimaldi; D Puigdemont; J Molet; J-R Caso; J-A Mico; V Pérez; J-C Leza; E Berrocoso
Journal:  Mol Psychiatry       Date:  2013-05-28       Impact factor: 15.992

7.  Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder.

Authors:  J A Cobb; K O'Neill; J Milner; G J Mahajan; T J Lawrence; W L May; J Miguel-Hidalgo; G Rajkowska; C A Stockmeier
Journal:  Neuroscience       Date:  2015-12-30       Impact factor: 3.590

8.  Effect of Electroconvulsive Therapy on Striatal Morphometry in Major Depressive Disorder.

Authors:  Benjamin S C Wade; Shantanu H Joshi; Stephanie Njau; Amber M Leaver; Megha Vasavada; Roger P Woods; Boris A Gutman; Paul M Thompson; Randall Espinoza; Katherine L Narr
Journal:  Neuropsychopharmacology       Date:  2016-04-12       Impact factor: 7.853

Review 9.  Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue.

Authors:  Grazyna Rajkowska; Craig A Stockmeier
Journal:  Curr Drug Targets       Date:  2013-10       Impact factor: 3.465

10.  Variations in myo-inositol in fronto-limbic regions and clinical response to electroconvulsive therapy in major depression.

Authors:  Stephanie Njau; Shantanu H Joshi; Amber M Leaver; Megha Vasavada; Jessica Van Fleet; Randall Espinoza; Katherine L Narr
Journal:  J Psychiatr Res       Date:  2016-05-28       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.